表紙：植物由来API市場- 世界の産業規模、シェア、動向、機会、予測、2018-2028年

市場調査レポート

商品コード

1326470

植物由来API市場- 世界の産業規模、シェア、動向、機会、予測、2018-2028年

Plant Based API Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type, By Application, By Region and Competition

出版日: 2023年08月01日 | 発行: TechSci Research

| ページ情報: 英文 111 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

Unprintable PDF (Single User License)

USD 4,900 771,897円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストはできません。PDFの印刷はできません。

PDF and Excel (Multi-User License)

USD 5,900 929,427円

レポートPDFおよびExcelデータシートを企業内でご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。レポート内のデータを含むExcelが併せて納品されます。Excelはライセンスを付与された企業の社内でのご利用が可能です。PDF内コンテンツの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF and Excel (Custom Research License)

USD 8,900 1,402,017円

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.53円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界の植物由来API市場は、天然で持続可能な製品に対する消費者の需要の高まりから、予測期間中に目覚ましい成長が見込まれています。

多くの消費者は、使用する製品が環境に与える影響を意識するようになり、天然で持続可能な代替品を求めるようになっています。その結果、多くの製薬会社がこの需要に応え、市場での差別化を図るために植物由来APIに目を向けるようになり、世界の植物由来API市場の成長を支えています。

植物由来医薬品への関心の高まり

伝統医学は長い間、植物の治癒力に依存しており、これらの自然療法の多くが幅広い疾患の治療に有効であることが示されています。その結果、植物由来医薬品の開発に対する関心が高まっており、植物由来原薬はこの動向の重要な要素となっています。その結果、様々な植物由来の医薬品が開発され、世界の植物由来医薬品原薬市場の成長を牽引しています。例えば、2018年、米国食品医薬品局（FDA）は、大麻植物に含まれる化合物であるカンナビジオール（CBD）から作られた医薬品であるEpidiolexを承認しました。この医薬品は、2歳以上の患者を対象に、レノックス・ガストー症候群とドラベ症候群という2つの稀なてんかんの治療に使用されます。エピディオレックスの承認は、西洋医学における植物由来の医薬品の使用における重要なマイルストーンとなっています。同様に2020年、FDAはタバコから作られたモノクローナル抗体であるSutimlimabを、寒冷凝集素病（CAD）の成人患者における溶血の治療薬として承認しました。Sutimlimabは植物由来のモノクローナル抗体として初めてFDAの承認を受けたもので、希少疾患の治療に植物由来の医薬品を使用する上で大きな前進となります。さらに2020年、FDAは輸血性鉄過剰症患者の治療に使用される鉄キレート剤Ferriproxを承認しました。Ferriproxは、黄熱病の木と呼ばれる植物に由来するデフェリプロンという植物由来の化合物から作られています。Ferriproxの承認は、サラセミア、鎌状赤血球貧血、その他の血液疾患患者にみられる輸血性鉄過剰症の患者に新たな治療選択肢を提供するものです。

植物ベースの製品に対する需要の高まりとともに、植物ベースの医薬品への関心が高まっていることから、植物ベースの医薬品有効成分に対する需要も確実に増加し、世界の植物ベースのAPI市場の成長を支えています。

慢性疾患の有病率の増加

がん、糖尿病、心臓病などの慢性疾患は増加傾向にあり、新しい効果的な治療法の必要性が高まっています。植物由来のAPIは、抗炎症作用や抗酸化作用など、幅広い健康上の利点があることが示されており、様々な医薬品の製造に使用されています。その結果、これらの慢性疾患の治療に使用されるいくつかの医薬品や治療法の植物由来バージョンが発売され、今後数年間の世界の植物由来API市場の成長に新たな展望が生まれています。例えば、パクリタキセルは乳がん、卵巣がん、肺がんなど様々ながんの治療に用いられる化学療法薬です。2020年、インドでパクリタキセルの植物由来バージョンが発売されました。この植物由来バージョンはイチイの木から作られ、何世紀にもわたってさまざまな病気の治療に使われてきました。パクリタキセルの植物由来バージョンは、再生可能な資源を使用して生産されるため、従来の合成バージョンよりも持続可能であると考えられています。同様に、ジゴキシンは心不全や特定の心拍障害の治療に用いられる薬です。2021年、植物由来のジゴキシンがインドで発売されました。この植物由来バージョンは、何世紀にもわたって伝統医療で使用されてきたジギタリス・ラナータと呼ばれる植物から作られています。ジゴキシンの植物由来バージョンは、石油化学製品を使用して生産される合成バージョンよりも持続可能な代替品と考えられています。

バイオテクノロジーとゲノミクスの進歩

ゲノミクスとバイオテクノロジーの進歩は、植物における活性化合物の生産を担う特定の遺伝子の同定と単離を可能にしました。これにより、活性化合物を大量に生産する新しい植物品種が開発され、新しい植物由来原薬の開発に利用できるようになり、世界の植物由来原薬市場の成長を支えています。これはまた、この分野への投資を行う世界中の様々な大小企業の注目を集め、それゆえ世界の植物由来API市場の成長を支えています。例えば、イスラエルのバイオ企業Kaiima Bio-Agritechは、高価値の植物由来APIを生産するための作物の遺伝子改良のためのプラットフォームを開発し、カナダのバイオ企業Ceaproは、医薬品やその他の製品に使用するための植物からの有効成分の抽出のための独自の技術を開発しました。

利用可能なカスタマイズ

TechSci Researchは、所定の市場データを用いて、企業固有のニーズに応じたカスタマイズを提供します。レポートでは以下のカスタマイズが可能です：

企業情報

追加市場プレイヤー（最大5社）の詳細分析とプロファイリング

Business Overview
Product Offerings
Recent Developments
Key Personnel
SWOT Analysis
- Roquette Freres SA
- EVONIK Industries, AG
- Cargill, Inc.
- Kothari Phytochemicals & Industries Ltd
- Medipure Pharmaceuticals Inc.
- Centroflora Group
- Arboris, LLCs
- BASF SE
- Novartis AG
- Sanofi SA
- GlaxoSmithKline, plc
- F. Hoffmann-La Roche AG

第16章戦略的提言

Product Code: 14866

Global Plant Based API Market is expected to grow at an impressive rate during the forecast period on account of the growing consumer demand for natural and sustainable products. Many consumers are becoming more conscious of the environmental impact of the products they use and are increasingly seeking out natural and sustainable alternatives. As a result, many pharmaceutical companies are now turning to plant-based APIs to meet this demand and differentiate themselves in the market, thereby supporting the growth of global plant based API market.

Plant-based APIs are derived from natural sources, such as herbs, spices, and other plants, and are used to produce a wide range of pharmaceuticals, including antibiotics, painkillers, and anticancer drugs. The growing demand for eco friendly products and need to achieve sustainability goals among countries and governments worldwide will create lucrative opportunities for the growth of global plant based API market in the next few years.

Another driver of the global plant-based API market is the growing interest in plant-based medicines. Traditional medicine has long relied on the healing properties of plants, and many of these natural remedies have been shown to be effective in treating a wide range of ailments. As a result, there is growing interest in the development of plant-based medicines, and plant-based APIs are a key component of this trend.

Growing Interest in Plant Based Medicines

Traditional medicine has long relied on the healing properties of plants, and many of these natural remedies have been shown to be effective in treating a wide range of ailments. As a result, there is a growing interest in the development of plant-based medicines, and plant-based APIs are a key component of this trend. This has in turn led to the development of various plant based pharmaceuticals thereby driving the growth of global plant based active pharmaceutical ingredient (API) market. For instance, in 2018, the U.S. Food and Drug Administration (FDA) approved Epidiolex, a drug made from cannabidiol (CBD), a compound found in the cannabis plant. This drug is used to treat two rare forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. The approval of Epidiolex marked a significant milestone in the use of plant-based pharmaceuticals in Western medicine. Similarly, in 2020, the FDA approved Sutimlimab, a monoclonal antibody made from tobacco plants, for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD). Sutimlimab is the first plant-based monoclonal antibody to receive FDA approval, and it is a significant step forward in the use of plant-based pharmaceuticals for the treatment of rare diseases. Additionally, in 2020, the FDA approved Ferriprox, an iron chelator used to treat patients with transfusional iron overload. Ferriprox is made from a plant-based compound called deferiprone, which is derived from a plant called the yellow fever tree. The approval of Ferriprox provides a new treatment option for patients with transfusional iron overload, which can occur in patients with thalassemia, sickle cell anemia, and other blood disorders.

The increasing interest in plant based pharmaceuticals along with growing demand for plant based products will certainly increase the demand for plant based active pharmaceutical ingredients as well, thereby supporting the growth of global plant based API market.

Increasing Prevalence of Chronic Diseases

Chronic diseases such as cancer, diabetes, and heart disease are on the rise, and there is a growing need for new and effective treatments. Plant based APIs have been shown to have a wide range of health benefits, including anti-inflammatory and antioxidant properties, and are being used to produce a wide range of pharmaceuticals. This has in turn contributed to the launch of plant based versions of several medicine or therapies that are used to treat these chronic conditions, thereby creating new prospects for the growth of global plant based API market in the next few years. For instance, Paclitaxel is a chemotherapy drug used to treat various cancers, including breast, ovarian, and lung cancer. In 2020, a plant-based version of paclitaxel was launched in India. This plant-based version is made from yew trees, which have been used for centuries to treat various ailments. The plant-based version of paclitaxel is considered to be more sustainable than the traditional synthetic version, as it is produced using renewable resources. Similarly, Digoxin is a medication used to treat heart failure and certain heart rhythm disorders. In 2021, a plant-based version of digoxin was launched in India. The plant-based version is made from a plant called Digitalis lanata, which has been used in traditional medicine for centuries. The plant-based version of digoxin is seen as a more sustainable alternative to the synthetic version, which is produced using petrochemicals.

Advances in Biotechnology and Genomics

The advancement in genomics and biotechnology has enabled the identification and isolation of specific genes responsible for the production of active compounds in plants. This has led to the development of new plant varieties that produce higher quantities of active compounds, which can be used to develop new plant-based APIs, thereby supporting the growth of global plant based API market. This has also attracted the focus of various small and big companies worldwide making investment into this space and hence supporting the growth of global plant based API market. For example, Israeli biotech company Kaiima Bio-Agritech has developed a platform for the genetic improvement of crops for the production of high-value plant-based APIs, while Canadian biotech company Ceapro has developed a proprietary technology for the extraction of active ingredients from plants for use in pharmaceuticals and other products.

Market Segmentation

Global Plant Based API Market can be segmented by type, by application, and by region. Based on type, the Global Plant Based API market can be categorized into alkaloids, anthocyanins, flavonoids, phenolic acids, terpenoids, lignans and stilbenes, and others. By application, the Global Plant Based API market can be fragmented into pharmaceuticals, nutraceuticals, herbal based industries, and others. Regionally, the Global Plant Based API market can be segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

Roquette Freres SA, EVONIK Industries, AG, Cargill, Inc., Kothari Phytochemicals & Industries Ltd, Medipure Pharmaceuticals Inc., Centroflora Group, Arboris, LLCs, BASF SE, Novartis AG, Sanofi SA, GlaxoSmithKline, plc, F. Hoffmann-La Roche AG, among others are some of the leading players operating in the Global Plant Based API market.

Recent Developments

In 2019, a team of researchers from the University of Wisconsin-Madison developed a new platform for producing plant-based APIs using genetically modified tobacco plants. The researchers were able to produce an anti-inflammatory protein called Interleukin-37 (IL-37) in tobacco plants and demonstrated that the protein was able to alleviate symptoms of inflammatory bowel disease in mice.
In 2019, Sanofi SA announced a USD 640 million (€600 million) investment in its French production sites, with a focus on plant-based APIs for the treatment of rare diseases. The investment will support the development of new plant-based technologies, including the use of algae and other microorganisms to produce APIs. Sanofi has also invested in the production of plant-based insulin, which was approved by the FDA in 2020.
Novartis has also made significant investments in plant-based APIs in recent years, with a focus on the use of plant cell culture technology. In 2020, Novartis announced a collaboration with Canadian biotech company PlantForm Corporation to develop plant-based biosimilars for the treatment of rare diseases. Novartis has also invested in the development of plant-based vaccines, including a collaboration with Boston-based biotech company VBI Vaccines to develop a plant-based vaccine for COVID-19.
In 2020, Amyris, a California-based biotechnology company, announced that it had successfully produced a plant-based version of the anti-malarial drug artemisinin. The company used a proprietary yeast strain to produce the drug, which was then licensed to pharmaceutical companies for further development and commercialization.
In 2021, researchers from the University of Bristol developed a method for producing a key component of the malaria drug artemisinin using genetically modified yeast. This approach offers a more sustainable and cost-effective alternative to traditional methods of producing the drug, which involve extracting it from the artemisia plant

Report Scope:

In this report, Global Plant Based API Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Plant Based API Market, By Type:

Alkaloids
Anthocyanins
Flavonoids
Phenolic Acids
Terpenoids
Lignans and Stilbenes
Others

Plant Based API Market, By Application:

Pharmaceuticals
Nutraceuticals
Herbal Based Industries
Others

Plant Based API Market, By Region:

North America
- United States
- Canada
- Mexico

Europe
- France
- Germany
- United Kingdom
- Italy
- Spain

Asia Pacific
- China
- India
- Japan
- South Korea
- Australia

South America
- Brazil
- Argentina
- Colombia

Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Plant Based API Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

植物由来API市場- 世界の産業規模、シェア、動向、機会、予測、2018-2028年

Plant Based API Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type, By Application, By Region and Competition

植物由来医薬品への関心の高まり

慢性疾患の有病率の増加

バイオテクノロジーとゲノミクスの進歩

利用可能なカスタマイズ

企業情報

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 植物由来APIの世界市場展望

第6章 北米の植物由来API市場展望

第7章 欧州の植物由来API市場の展望

第8章 アジア太平洋の植物由来API市場展望

第9章 南米の植物由来API市場の展望

第10章 中東・アフリカの植物由来API市場の展望

第11章 市場力学

第12章 市場動向と発展

第13章 世界の植物由来API市場SWOT分析

第14章 ポーターのファイブフォース分析

第15章 競合情勢

第16章 戦略的提言

Growing Interest in Plant Based Medicines

Increasing Prevalence of Chronic Diseases

Advances in Biotechnology and Genomics

Market Segmentation

Market Players

Recent Developments

Report Scope:

Plant Based API Market, By Type:

Plant Based API Market, By Application:

Plant Based API Market, By Region:

Competitive Landscape

Available Customizations:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Plant Based API Market Outlook

6. North America Plant Based API Market Outlook

7. Europe Plant Based API Market Outlook

8. Asia-Pacific Plant Based API Market Outlook

9. South America Plant Based API Market Outlook

10. Middle East and Africa Plant Based API Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Global Plant Based API Market: SWOT Analysis

14. Porter's Five Forces Analysis

15. Competitive Landscape

16. Strategic Recommendations

第1章概要

第2章調査手法

第3章エグゼクティブサマリー

第4章顧客の声

第5章植物由来APIの世界市場展望

第6章北米の植物由来API市場展望

第7章欧州の植物由来API市場の展望

第8章アジア太平洋の植物由来API市場展望

第9章南米の植物由来API市場の展望

第10章中東・アフリカの植物由来API市場の展望

第11章市場力学

第12章市場動向と発展

第13章世界の植物由来API市場SWOT分析

第14章ポーターのファイブフォース分析

第15章競合情勢

第16章戦略的提言